口服对比增强经腹超声与横断面对比增强CT在进展期胃癌术前肿瘤分期中的比较
回顾性纳入42例因严重并发症接受腹腔镜、根治或姑息手术且BMI<25 kg/m²的进展期胃癌患者,比较口服对比增强经腹超声与横断面对比增强CT按第7版TNM分期的准确性。两种方法总体准确率无显著差异(超声86% vs CT 83%,P>.999);超声在T2、T3、T4期的准确率分别为88%、86%、98%,CT分别为93%、83%、90%。
要点
- 口服对比增强经腹超声与横断面对比增强CT的总体分期准确率无显著差异(86% vs 83%,P>.999)。
- T4期超声准确率98%,高于CT的90%;T2期超声88%,低于CT的93%。
- 分期标准为第7版TNM分类,由2名有经验的放射科医师独立评估。
核心结论
- 口服对比增强经腹超声对进展期胃癌术前肿瘤分期的总体准确率与横断面对比增强CT相当。
研究设计与样本
- 回顾性研究,纳入42例因严重并发症接受腹腔镜、根治或姑息手术且BMI<25 kg/m²的进展期胃癌患者,采用谷物基口服对比剂行经腹超声,并与横断面对比增强CT对照,由2名有经验的放射科医师独立按第7版TNM分类评估,以病理结果为参考标准。
诊断标准与关键数值
- 总体准确率:口服对比增强超声86%(42例中36例)vs 横断面对比增强CT 83%(42例中35例),P>.999。T2期准确率:超声88% vs CT 93%。T3期准确率:超声86% vs CT 83%。T4期准确率:超声98% vs CT 90%。
临床应用与阅片要点
- 作者结论认为口服对比增强经腹超声对进展期胃癌术前肿瘤分期的总体准确率与横断面对比增强CT相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study assessed the diagnostic performance of transabdominal oral contrast-enhanced ultrasound (US) imaging for preoperative tumor staging of advanced gastric carcinoma by comparing it with transverse contrast-enhanced computed tomography (CT).
METHODS: This retrospective study included 42 patients with advanced gastric cancer who underwent laparoscopy, radical surgery, or palliative surgery because of serious complications and had a body mass index of less than 25 kg/m2 . A cereal-based oral contrast agent was used for transabdominal oral contrast-enhanced US. Retrospective analyses were conducted using preoperative tumor staging data acquired by either transabdominal oral contrast-enhanced US or transverse contrast-enhanced CT. Both contrast-enhanced US and contrast-enhanced CT examinations were reviewed by 2 experienced radiologists independently for preoperative tumor staging according to the seventh edition of the TNM classification. The accuracy, sensitivity, and specificity were calculated by comparing the results of contrast-enhanced US and contrast-enhanced CT with pathologic findings. The overall accuracies of the imaging modalities were compared by the McNemar test.
RESULTS: No significant difference was noted in the overall accuracy of transabdominal oral contrast-enhanced US (86% [36 of 42]) and transverse contrast-enhanced CT (83% [35 of 42] P > .999). For stage T2 to T4 gastric cancer, the accuracies of transabdominal oral contrast-enhanced US were 88%, 86%, and 98%, respectively, and those of transverse contrast-enhanced CT were 93%, 83%, and 90%.
CONCLUSIONS: The overall accuracy of transabdominal oral contrast-enhanced US was comparable with that of transverse contrast-enhanced CT for preoperative tumor staging of advanced gastric cancer.
引用
- He X, Sun J, Huang X, et al. Comparison of Oral Contrast-Enhanced Transabdominal Ultrasound Imaging With Transverse Contrast-Enhanced Computed Tomography in Preoperative Tumor Staging of Advanced Gastric Carcinoma. J Ultrasound Med. 2017. PMID: 28646603. doi:10.1002/jum.14290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。